Investor directory

Palisade Bio

Palisade Bio is a clinical-stage biopharmaceutical company based in Carlsbad, California, founded in 2011. The company specializes in developing therapeutics aimed at diseases related to compromised gastrointestinal barrier integrity. Its primary focus is on addressing unmet medical needs through scientifically grounded treatments. Palisade Bio's portfolio includes PALI-2108, which is being developed for the treatment of inflammatory bowel disease, encompassing conditions such as ulcerative colitis and Crohn's disease. Additionally, the company is researching PALI-1908 as part of its commitment to advancing innovative therapies in this area.

Top Stages

Acquisition
http://www.palisadebio.com
https://senecabio.com
https://crunchbase.com/organization/seneca-biopharma
https://facebook.com/palisadebio
https://linkedin.com/company/palisadebio
https://twitter.com/palisadebio
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=7728881

Mitchell Jones

Chief Medical Officer

Robert McRae

COO

1 past transactions

Leading BioSciences, Inc.

Acquisition in 2020
Leading BioSciences, Inc. (LBS) is a biopharmaceutical company that has developed a revolutionary medical platform based on the science of autodigestion. The company’s lead candidate (LB1148) is a therapeutic for severe sepsis, septic shock, and multi-organ failure. In addition, the company is developing a breath and blood diagnostic for early detection of acute shock and multi-organ failure. This therapy is part of an overall product design that includes the pharmaceutical formulation (LB1148) and the delivery device. To date, this new medical platform has produced 14 different products, therapies, and medical devices each with their own distinct patents and exclusive licenses.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.